Corbus Pharmaceuticals Holdings, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $724.86 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-03-07
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $189.82K, a 31.74% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $184.00K, a 255.97% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-12-31 was $278.09K.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-09-30 was $51.69K.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $724.86K, a 13.36% increase from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $639.41K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $189.82K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $373.82K derived: sum of 2 quarters · filed 2023-03-07 | $724.86K 10-K · filed 2023-03-07 | |
| 2022-09-30 | $184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $535.04K 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $351.03K 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $278.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $329.78K derived: sum of 2 quarters · filed 2023-03-07 | $639.41K 10-K · filed 2023-03-07 | |
| 2021-09-30 | $51.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $361.33K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $309.64K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |